CRISPR Therapeutics AG (CRSP) Cash & Current Investments (2015 - 2026)

CRISPR Therapeutics AG has disclosed Cash & Current Investments across 12 years of filings, most recently posting $2.4 billion for Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $2.4 billion, up 31.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.4 billion (up 31.61% YoY), and the FY2025 annual result was $2.0 billion, up 23.06% from the prior year.
• Cash & Current Investments came in at $2.4 billion for Q1 2026 at CRISPR Therapeutics AG, up from $2.0 billion in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $2.4 billion in Q1 2026 to a low of $1.6 billion in Q4 2024.
• The 5-year median for Cash & Current Investments is $1.9 billion (2022), against an average of $1.9 billion.
• Across the five-year window, Cash & Current Investments decreased 23.7% in 2022 and soared 31.61% in 2026, its largest moves.
• CRISPR Therapeutics AG's Cash & Current Investments stood at $1.8 billion in 2022, then fell by 6.7% to $1.7 billion in 2023, then decreased by 5.2% to $1.6 billion in 2024, then increased by 23.06% to $2.0 billion in 2025, then advanced by 23.58% to $2.4 billion in 2026.
• The last three Cash & Current Investments figures came in at $2.4 billion (Q1 2026), $2.0 billion (Q4 2025), and $1.9 billion (Q3 2025), per Business Quant data.